Xeris Biopharma Holdings, Inc. (XERS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.53-0.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XERS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 335.4 | 291.8 | 203.1 | 163.9 | 110.2 | 49.6 | 20.4 |
| Total Revenues | — | — | — | — | — | 49.6 | 20.4 |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | 208.1 | 182.4 | 163.5 | 146.1 | 137.7 | 125.7 | 73.7 |
| R&D Expenses | 34.8 | 31.2 | 25.6 | 22.3 | 21.0 | 25.2 | 20.9 |
| Operating Income | 36.6 | 24.9 | (33.6) | (44.0) | (81.9) | (115.2) | (83.5) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 29.1 | 30.5 | 26.6 | 14.1 | 7.2 | 10.7 |
| EBT, Incl. Unusual Items | — | 0.6 | (57.1) | (63.5) | (96.1) | (122.7) | — |
| Income Tax Expense | — | — | (2.3) | (1.2) | (1.4) | 0.0 | (0.1) |
| Net Income | |||||||
| Net Income | (17.2) | 0.6 | (54.8) | (62.3) | (94.7) | (122.7) | (91.1) |
| Per Share | |||||||
| Basic EPS | (0.10) | — | (0.37) | (0.45) | (0.70) | (1.55) | — |
| Diluted EPS | (0.10) | — | (0.37) | (0.45) | (0.70) | (1.55) | — |
| Revenue per Share | 1.94 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 172.8 | 160.4 | 146.8 | 137.7 | 135.6 | 79.0 | — |
| Diluted Weighted Avg Shares | 172.8 | 172.7 | 146.8 | 137.7 | 135.6 | 79.0 | — |
| Supplemental | |||||||
| EBITDA | — | 26.2 | (32.4) | (42.5) | (80.5) | (113.8) | (82.1) |
| EBIT | 36.6 | 24.9 | (33.6) | (44.0) | (81.9) | (115.2) | (83.5) |
| Effective Tax Rate | — | — | — | 2.0% | 1.5% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.